- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.06. | Hemogenyx Pharmaceuticals PLC Announces Notice of AGM | 189 | ACCESS Newswire | Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Posting of Annual Report & Notice of Annual General Meeting LONDON, UK / ACCESS Newswire / June 5, 2026 / Hemogenyx Pharmaceuticals... ► Artikel lesen | |
| HEMOGENYX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 05.06. | Hemogenyx Pharma Plc - Notice of AGM | - | RNS | ||
| 29.05. | Hemogenyx Pharmaceuticals PLC Announces Grant of Options and Extension of Warrant Term | 226 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 29.05. | Hemogenyx Pharmaceuticals gibt neue Aktienoptionen aus und verlängert Laufzeit von Optionsscheinen | 2 | Investing.com Deutsch | ||
| 29.05. | Hemogenyx Pharma Plc - Grant of Options and Extension of Warrant Term | 1 | RNS | ||
| 30.04. | Hemogenyx Pharmaceuticals PLC Announces Final Results | 217 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 30.04. | Hemogenyx Pharma Plc - Final Results | 3 | RNS | ||
| 28.04. | Hemogenyx Pharmaceuticals PLC Announces Institutional Fundraise | 207 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 28.04. | Hemogenyx Pharma Plc - Institutional Fundraise | 3 | RNS | ||
| 14.04. | Hemogenyx Pharmaceuticals PLC Announces Annual IND Report with FDA | 307 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 14.04. | Hemogenyx Pharma Plc - Annual IND Report with FDA | 1 | RNS | ||
| 31.03. | Hemogenyx Pharmaceuticals PLC Announces Tech Transfer Completion and Clinical Trial Update | 156 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 31.03. | Hemogenyx completes tech transfer for CAR-T therapy to CDMO | 4 | Investing.com | ||
| 31.03. | Hemogenyx: Technologietransfer für CAR-T-Therapie erfolgreich abgeschlossen | 2 | Investing.com Deutsch | ||
| 31.03. | Hemogenyx Pharma Plc - Tech Transfer Completion and Clinical Trial Update | 2 | RNS | ||
| 27.02. | Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights | 307 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / February 27, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the... ► Artikel lesen | |
| 27.02. | Hemogenyx Pharma Plc - Total Voting Rights | 3 | RNS | ||
| 23.02. | Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity | 282 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 23.02. | Hemogenyx Pharma Plc - Exercise of Warrants and Issue of Equity | 1 | RNS | ||
| 10.02. | Hemogenyx Pharmaceuticals PLC Announces Issue of Equity | 577 | ACCESS Newswire | The sentence "through a direct subscription for 313,333 new ordinary shares in the Company at a price of £7.50 per share" has been corrected to "through a direct subscription for 333,333 new ordinary... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 2,160 | +0,93 % | EILMELDUNG bei InnoCan Pharma: Was Insider heute bereits wissen - Meine klare Einschätzung dazu | ||
| NOVERIS HEALTH SCIENCES | 1,460 | 0,00 % | Noveris Health Sciences Inc: Noveris Health appoints Griffiths as strategic adviser | ||
| PEAKBIRCH COMMERCE | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.02.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 02.02.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.02.2026ISIN NameCA70470T2092 PEAKBIRCH... ► Artikel lesen | |
| GELTEQ | 1,530 | 0,00 % | Gelteq Limited: Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway | MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq") today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq... ► Artikel lesen | |
| BAYER | 35,920 | +0,36 % | Iran-Krieg: DAX schwächer, Öl höher, Asien tiefrot - Apple, BASF, Infineon, Bayer, Porsche ... | Der DAX hat am Freitag weitere Verluste hinnehmen müssen. Der deutsche Leitindex verlor 0,8 Prozent auf 24.759,05 Punkte. Auf Wochensicht summierten sich die Verluste sogar auf 1,4 Prozent. Und auch... ► Artikel lesen | |
| MERCK KGAA | 136,90 | +1,11 % | EQS-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Merck KGaA
Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
08.06.2026 / 16:57 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 61,57 | 0,00 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| NOVO NORDISK | 37,740 | +0,32 % | Novo Nordisk seit Marktstart mit 3 Mio Verschreibungen der Wegovy-Pille | DJ Novo Nordisk seit Marktstart mit 3 Mio Verschreibungen der Wegovy-Pille
Von Dominic Chopping
DOW JONES--Das Adipositasmedikament von Novo Nordisk ist auch in der Tablettenform sehr erfolgreich.... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 32,080 | -0,09 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| GENERATE BIOMEDICINES | 12,910 | -0,15 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| ELI LILLY | 1.003,40 | +0,10 % | Zelltherapien rücken in den Mittelpunkt: Warum Mesoblast von einem grundlegenden Wandel in der Biotechnologie profitieren könnte | ||
| AQUESTIVE THERAPEUTICS | 4,205 | -0,12 % | Aquestive Therapeutics, Inc. - 8-K, Current Report | ||
| ATRIUM THERAPEUTICS | 12,430 | 0,00 % | Atrium Therapeutics Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 12,610 | +0,56 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| PMGC | 1,570 | +0,64 % | PMGC Holdings Inc.: NorthStrive Defense Tech Executes Binding Agreement to Acquire Exclusive License to Patented Multi-Domain Drone Payload Technology for Defense, Aerospace and Maritime Applications | Binding term sheet for an exclusive, worldwide, sublicensable license in the aerospace and defense field to a granted U.S. patent covering autonomous, buoyancy-assisted transport of payloads across... ► Artikel lesen |
HEMOGENYX PHARMACEUTICALS PLC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 8,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOGENYX PHARMACEUTICALS PLC finden Sie auf Wallstreet Online.